State of the art in pediatric nanomedicines
- PMID: 38324166
- DOI: 10.1007/s13346-024-01532-x
State of the art in pediatric nanomedicines
Abstract
In recent years, the continuous development of innovative nanopharmaceuticals is expanding their biomedical and clinical applications. Nanomedicines are being revolutionized to circumvent the limitations of unbound therapeutic agents as well as overcome barriers posed by biological interfaces at the cellular, organ, system, and microenvironment levels. In many ways, the use of nanoconfigured delivery systems has eased challenges associated with patient differences, and in our opinion, this forms the foundation for their potential usefulness in developing innovative medicines and diagnostics for special patient populations. Here, we present a comprehensive review of nanomedicines specifically designed and evaluated for disease management in the pediatric population. Typically, the pediatric population has distinguishing needs relative to those of adults majorly because of their constantly growing bodies and age-related physiological changes, which often need specialized drug formulation interventions to provide desirable therapeutic effects and outcomes. Besides, child-centric drug carriers have unique delivery routes, dosing flexibility, organoleptic properties (e.g., taste, flavor), and caregiver requirements that are often not met by traditional formulations and can impact adherence to therapy. Engineering pediatric medicines as nanoconfigured structures can potentially resolve these limitations stemming from traditional drug carriers because of their unique capabilities. Consequently, researchers from different specialties relentlessly and creatively investigate the usefulness of nanomedicines for pediatric disease management as extensively captured in this compilation. Some examples of nanomedicines covered include nanoparticles, liposomes, and nanomicelles for cancer; solid lipid and lipid-based nanostructured carriers for hypertension; self-nanoemulsifying lipid-based systems and niosomes for infections; and nanocapsules for asthma pharmacotherapy.
Keywords: Cancer therapy; Nanomedicines; Nanopharmaceuticals; Nanotechnology; Pediatric drug delivery; Polymeric nanocarriers.
© 2024. Crown.
Similar articles
-
Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug.Pharm Nanotechnol. 2024;12(3):229-250. doi: 10.2174/2211738511666230816090046. Pharm Nanotechnol. 2024. PMID: 37587812 Review.
-
Advances and challenges in nanocarriers and nanomedicines for veterinary application.Int J Pharm. 2020 Apr 30;580:119214. doi: 10.1016/j.ijpharm.2020.119214. Epub 2020 Mar 9. Int J Pharm. 2020. PMID: 32165220 Review.
-
Recent advances in functional lipid-based nanomedicines as drug carriers for organ-specific delivery.Nanoscale. 2025 Mar 28;17(13):7617-7638. doi: 10.1039/d4nr04778h. Nanoscale. 2025. PMID: 40026004 Review.
-
Evaluating Nanomedicines: Obstacles and Advancements.Methods Mol Biol. 2018;1682:3-16. doi: 10.1007/978-1-4939-7352-1_1. Methods Mol Biol. 2018. PMID: 29039088
-
Biological rationale for the design of polymeric anti-cancer nanomedicines.J Drug Target. 2013 Jan;21(1):1-26. doi: 10.3109/1061186X.2012.723213. Epub 2012 Sep 26. J Drug Target. 2013. PMID: 23009337 Free PMC article. Review.
Cited by
-
Leading Paediatric Infectious Diseases-Current Trends, Gaps, and Future Prospects in Oral Pharmacotherapeutic Interventions.Pharmaceutics. 2024 May 26;16(6):712. doi: 10.3390/pharmaceutics16060712. Pharmaceutics. 2024. PMID: 38931836 Free PMC article. Review.
References
-
- Lehmann B. Regulation (EC) No 1901/2006 on medicinal products for paediatric use & clinical research in vulnerable populations. Child Adolesc Psychiatry Ment Health. 2008;2:37. https://doi.org/10.1186/1753-2000-2-37 . - DOI - PubMed - PMC
-
- Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT. Summary of the National Institute of Child Health and Human Development-Best Pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. Clin Ther. 2012;34:S11–24. https://doi.org/10.1016/j.clinthera.2012.09.014 . - DOI - PubMed - PMC
-
- Avant D, Wharton GT, Murphy D. Characteristics and changes of pediatric therapeutic trials under the Best Pharmaceuticals for Children Act. J Pediatr. 2018;192:8–12. https://doi.org/10.1016/j.jpeds.2017.08.048 . - DOI - PubMed
-
- Ren Z, Zajicek A. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: what can the obstetric community learn from the pediatric experience? Semin Perinatol. 2015;39:530–1. https://doi.org/10.1053/j.semperi.2015.08.006 . - DOI - PubMed - PMC
-
- Turner MA, Catapano M, Hirschfeld S, Giaquinto C. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev. 2014;73:2–13. https://doi.org/10.1016/j.addr.2014.02.003 . - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous